Want to see HSDT full AI Analyst Report?
Top Page
Solana Company
(NASDAQ:HSDT)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.00
▲(46.34% Upside)
Action:Reiterated
Date:09/24/26
The score is held back primarily by weak financial performance (large losses and sustained cash burn) despite low leverage. Offsetting factors include strong technical momentum and a moderately constructive earnings outlook tied to validator revenue and scaling initiatives, but valuation signals are limited due to negative earnings and no dividend support.
Positive Factors
Staking Revenue Growth
Staking has created a meaningful revenue stream where little existed previously, demonstrating initial monetization of the treasury strategy. If validator operations and delegated stake scale as planned, this expanding base could support recurring revenue growth over the next several quarters.
Negative Factors
Deep Operating Losses
Losses remain far larger than the current revenue base, so rapid top-line growth has not yet translated into sustainable profitability. Continued operating deficits could dilute the benefits of staking expansion and require management to reduce expenses or secure additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Staking Revenue Growth
Staking has created a meaningful revenue stream where little existed previously, demonstrating initial monetization of the treasury strategy. If validator operations and delegated stake scale as planned, this expanding base could support recurring revenue growth over the next several quarters.
Read all positive factors
Solana Company (HSDT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$177.75M
Dividend YieldN/A
Average Volume (3M)489.41K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth3992.20%
EPS Growth98.48%
CountryUS
Employees21
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-30.32
Shares Outstanding60,458,702
10 Day Avg. Volume730,964
30 Day Avg. Volume489,413
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.21
Price to Sales (P/S)10.59
P/FCF Ratio-1.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside70.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$11.45M
Solana Company Business Overview & Revenue Model
Company Description
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technolog...
Solana Company Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The call presented a mix of meaningful operational progress and strategic milestones—validator cluster live in Tokyo, first institutional stake (~0.5M SOL), partnerships (Jito, Alatau), acquisition of a Hong Kong trust company, strong staking yields and year-over-year revenue growth—while also disclosing substantial near-term financial headwinds including large GAAP losses, realized and unrealized digital asset losses driven by SOL price declines, elevated operating expenses (including a $6.8M severance charge), and a low cash balance. Management emphasized the long-term flywheel strategy and expected near-term revenue recognition from validator operations, but the company remains in transition with material volatility in reported earnings.Positive Updates
Validator Infrastructure Launched in Tokyo
First institutional validated cluster became operational (early July) with 3 machines constituting one validator cluster in Tokyo; initial institutional third-party stake commitment of ~0.5 million SOL secured in July and validator-related revenue expected to be reported in Q3 2026.
Negative Updates
Large Reported Net Losses
Net loss for Q2 2026 was $30.3 million ($0.38 per share) and year-to-date net loss was $130.1 million ($1.66 per share), compared with a Q2 2025 net loss of $9.8 million (increase of ~209% year-over-year for the quarter).
Read all updates
Q2-2026 Updates
Positive
Negative
Validator Infrastructure Launched in Tokyo
First institutional validated cluster became operational (early July) with 3 machines constituting one validator cluster in Tokyo; initial institutional third-party stake commitment of ~0.5 million SOL secured in July and validator-related revenue expected to be reported in Q3 2026.
Read all positive updates
Company Guidance
Management guided that they expect to begin recognizing validator-related revenue and report results from their first third‑party delegated stake in Q3 2026 — including recognition of the inaugural validator rewards — as they scale Pacific Backbone beyond the live Tokyo cluster (3 machines = 1 cluster) and the ~0.5 million SOL external stake secured in July; they also plan to convert the advisory pipeline into paid engagements and build recurring fee‑based infrastructure revenue while pursuing ISO 27001 and SOC 2, launching additional APAC validators over the year, and normalizing G&A back toward Q1 levels. Capital allocation will remain focused on maximizing SOL per share: Q2 buybacks totaled ~$2.3 million (retiring 1.3 million shares), YTD repurchases are ~ $5.9 million, mNAV rose to ~0.81x from 0.73x, and management said they will continue opportunistic repurchases while shares trade below NAV. Key operating metrics they cited to underpin guidance include ~2.3 million SOL held (fair value ≈ $170.6M) as of June 30, Q2 staking rewards of $2.5M (≈31,200 SOL), an average net staking yield of 6.14% APY versus a network ~5.68% (outperformance ~46 bps), total assets of $176.1M (cash $3.6M, long‑term digital assets $147.3M), and completion of the $2M Hong Kong trust acquisition on July 15.Solana Company Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.07M | 6.02M | 520.00K | 644.00K | 787.00K | 522.00K |
| Gross Profit | 11.53M | 5.52M | -62.00K | 61.00K | 324.00K | 224.00K |
| EBITDA | -135.02M | -39.58M | -13.80M | -12.11M | -14.50M | -17.82M |
| Net Income | -157.27M | -40.89M | -11.74M | -8.85M | -14.07M | -18.13M |
Balance Sheet | ||||||
| Total Assets | 176.05M | 303.93M | 3.54M | 7.69M | 17.29M | 14.10M |
| Cash, Cash Equivalents and Short-Term Investments | 3.65M | 7.28M | 1.09M | 5.18M | 14.55M | 11.01M |
| Total Debt | 0.00 | 0.00 | 12.00K | 57.00K | 110.00K | 3.00K |
| Total Liabilities | 10.41M | 3.02M | 2.48M | 5.34M | 9.14M | 2.85M |
| Stockholders Equity | 165.65M | 300.91M | 1.06M | 2.35M | 8.15M | 11.26M |
Cash Flow | ||||||
| Free Cash Flow | -26.94M | -61.29M | -11.05M | -10.45M | -14.33M | -13.44M |
| Operating Cash Flow | -26.94M | -16.51M | -11.04M | -10.42M | -14.31M | -13.39M |
| Investing Cash Flow | -415.59M | -426.53M | -5.00K | -29.00K | -11.00K | -56.00K |
| Financing Cash Flow | 440.10M | 449.24M | 6.95M | 1.08M | 17.87M | 21.13M |
Solana Company Technical Analysis
Positive
2.05
Price Trends
2.08
Positive
1.95
Positive
2.18
Positive
Market Momentum
0.26
Negative
61.61
Neutral
57.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSDT, the sentiment is Positive. The current price of 2.05 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.08, and below the 200-day MA of 2.18, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 61.61 is Neutral, neither overbought nor oversold. The STOCH value of 57.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HSDT.
Solana Company Risk Analysis
Solana Company disclosed 45 risk factors in its most recent earnings report. Solana Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Solana Company Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | $339.37M | 24.15 | 10.30% | ― | 25.21% | 6.14% | |
58 Neutral | $491.94M | -16.60 | -50.64% | ― | 9.27% | 41.98% | |
54 Neutral | $177.75M | -0.09 | -122.85% | ― | 3992.20% | 98.48% | |
52 Neutral | $57.27M | -0.72 | -62.25% | ― | -1.26% | 79.82% | |
51 Neutral | $43.36M | 2.78 | 1728.10% | ― | 12.02% | ― | |
45 Neutral | $71.93M | -1.31 | -152.35% | ― | 11.96% | 6.12% |
* Financial Sector Average
HSDT
Solana Company
2.84
-11.57
-80.29%
SNWV
Sanuwave Health
4.65
-29.95
-86.56%
VMD
Viemed Healthcare
9.11
2.49
37.61%
OM
Outset Medical
2.96
-11.53
-79.57%
CVRX
CVRx
2.59
-5.19
-66.71%
SGHT
Sight Sciences
9.27
5.79
166.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.